Mometasone
Unchecked
From Pharmacopedia
More actions
Mometasone furoate
Nasonex (intranasal), Asmanex (inhaled), Elocon (topical), Sinuva (sinus implant); with formoterol as Dulera
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Allergic rhinitis (intranasal)0, Nasal polyps (intranasal, sinus implant)0, Asthma controller (inhaled)0, Inflammatory dermatoses (topical)0
Pharmacy
Starting dose
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily
Preparations
Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol)
US FDA Max
Intranasal 200 mcg/d (adults); inhaled 880 mcg/d
Pharmacology
Routes
Intranasal, inhaled, topical, intranasal sinus implant
Onset
Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks
Duration
24 hours
Half-life
~5 hours (plasma)[1]
Bioavailability
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance[1]
Pregnancy
Intranasal long considered acceptable; widely used in obstetric rhinitis.[citation needed]
Legal status
OTC (Nasonex 24HR) and Rx-only (other forms) in US
Purported mechanism
Mometasone furoate is a high-affinity glucocorticoid receptor agonist with extensive hepatic first-pass clearance (CYP3A4) that minimizes systemic glucocorticoid exposure from inhaled, intranasal, or topical administration.0 Like other locally-acting corticosteroids, broadly suppresses inflammatory gene transcription; clinical onset is gradual for asthma controller use but rapid for allergic rhinitis. Once-daily intranasal dosing reflects strong receptor binding and slow tissue clearance[1].
References
edit- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Nasonex (mometasone furoate), Organon/Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020762s048lbl.pdf